drugset
drugset / Trial / NCT04184492

A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects

NCT04184492 ↗

Completed 34 enrolled Geropharm
RandomizedCrossoverSingle-blindBasic science

Summary

Pharmacokinetics and pharmacodynamics study of 2 formulations of biphasic insulin aspart 30 (GP-40081 GEROPHARM vers. NovoMix® 30 Penfill® Novo Nordisk)

Timeline

Start
2019-04-15
Primary completion
2019-06-28
Completion
2019-06-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator biphasic insulin aspart 30 Protein / enzyme biologic 0.4 iu/kg Subcutaneous

Indications

No indication recorded.